Extension block with Kirschner wire for fracture dislocation of the distal interphalangeal joint.

T. Ishiguro,Y. Itoh,Y. Yabe,Nobuharu Hashizume

DOI: https://doi.org/10.1097/00130911-199706000-00005

1997-06-01

Abstract:Extension Block with Kirschner Wire for Fracture Dislocation of the Distal Interphalangeal Joint TAKASHI ISHIGURO;YOSHIYASU ITOH;YUTAKA YABE;NOBUHARU HASHIZUME; Techniques in Hand & Upper Extremity Surgery

What problem does this paper attempt to address?

Effect of imatinib on oral wound healing after extraction: A rare case report

Alan L Myers,Sudarat Kiat-Amnuay,Bing-Yan Wang

DOI: https://doi.org/10.1016/j.adaj.2022.03.009

Abstract:Background: Proper tissue repair and healing after oral surgery are vital to achieve optimal outcomes. Certain medications may interfere with wound healing, but this debilitating adverse drug reaction is often not reported in the literature. It is unknown whether imatinib (Gleevec; Novartis Pharmaceuticals) interferes with gingival healing after oral surgery. Case description: A 58-year-old man with a dislodged crown and core buildup of tooth no. 19 sought treatment at a prosthodontic clinic. After examination, the patient consented to extraction, ridge preservation, and future implant placement. He had previous surgical resection of a gastrointestinal stromal tumor and was taking 400 mg of imatinib daily. After extraction and ridge preservation, delayed soft-tissue healing and loss of the coronal portion of bone graft were observed at 8 weeks after surgery. Delayed wound healing was observed again after revision surgery. After imatinib therapy was paused, the adverse effect subsided and the wound healed properly. On the basis of causality assessment and clinical judgment, the authors determined that imatinib was the probable cause of this adverse drug reaction. To their best knowledge, this is the first report of delayed gingival healing after oral surgery secondary to imatinib. Practical implications: Dental practitioners should consider the possibility of impaired healing among their patients taking imatinib, especially before procedures that damage gingival tissue, although this adverse drug reaction is not reported in the drug's package insert. Consult with the patient's oncologist is advised before dental manipulations; temporary discontinuation (or dose reductions) of imatinib may be warranted until wounded tissue heals properly.
Imatinib mesylate-induced lichenoid drug eruption

Erin H Penn,Hye Jin Chung,Matthew Keller

Cutis

Abstract:Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes to avoid unnecessarily discontinuing a potentially lifesaving medication. Adverse cutaneous manifestations in response to imat-inib are not infrequent and can include dry skin, alopecia, facial edema, and photosensitivity rash. Other less common manifestations include exfoliative dermatitis, nail disorders, psoriasis, folliculitis, hypotrichosis, urticaria, petechiae, Stevens-Johnson syndrome, erythema multiforme, Sweet syndrome, and leukocytoclastic vasculitis. We report a case of imatinib-induced lichenoid drug eruption (LDE), a rare cutaneous manifestation, along with a review of the literature.
Imatinib mesylate-induced acute hepatotoxicity

Imen Frikha,Yousra Fakhfakh,Rim Sahnoun,Lassaad Chtourou,Moez Medhaffar,Moez Elloumi

DOI: https://doi.org/10.1177/10781552231188307

2023-07-21

Journal of Oncology Pharmacy Practice

Abstract:Journal of Oncology Pharmacy Practice, Ahead of Print. IntroductionImatinib is a first-line selective tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia. Although imatinib-induced hepatotoxicity may aggravate the patient's clinical condition and alter the treatment plan, the mechanism of imatinib-induced hepatotoxicity has rarely been investigated.Case reportWe report a 51-year-old man, suffering from acute toxic hepatitis after 5 months of imatinib treatment for chronic myeloid leukemia.Management and outcomeThe outcome was favorable after discontinuation of treatment with normalization of biological liver function after 12 weeks. The treatment was switched to nilotinib without any incidents.DiscussionRegular liver function test monitoring is recommended during imatinib treatment. In fact of acute hepatic toxicity, treatment with imatinib should be stopped in the case of cytolysis more than five times the upper limit of normal.

oncology,pharmacology & pharmacy
Hypotensive Effects of Interval vs. Continuous Aerobic Exercise in Metabolic Syndrome Patients.: 1950 Board #102 June 2, 2: 00 PM - 3: 30 PM.

Felix Morales Palomo,M. Ramirez-Jimenez,J. Ortega,R. Mora‐Rodriguez

DOI: https://doi.org/10.1249/01.mss.0000486623.99299.3c

2016-05-01

Medicine & Science in Sports & Exercise

Abstract:
Imatinib Therapy of Chronic Myeloid Leukemia Significantly Reduces Carnitine Cell Intake, Resulting in Adverse Events

Pavel Burda,Alzbeta Hlavackova,Vendula Polivkova,Nikola Curik,Adam Laznicka,Jitka Krizkova,Jiri Suttnar,Pavel Klener,Katerina Machova Polakova

DOI: https://doi.org/10.1016/j.molmet.2024.102016

2024-08-23

Abstract:Objective: A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A substantial part of patients treated with imatinib report skeletomuscular adverse events affecting their quality of life. OCTN2 membrane transporter is involved in imatinib transportation into the cells. At the same time, the crucial physiological role of OCTN2 is cellular uptake of carnitine which is an essential co-factor for the mitochondrial β-oxidation pathway. This work investigates the impact of imatinib treatment on carnitine intake and energy metabolism of muscle cells. Methods: HTB-153 (human rhabdomyosarcoma) cell line and KCL-22 (CML cell line) were used to study the impact of imatinib treatment on intracellular levels of carnitine and vice versa. The energy metabolism changes in cells treated by imatinib were quantified and compared to changes in cells exposed to highly specific OCTN2 inhibitor vinorelbine. Mouse models were used to test whether in vitro observations are also achieved in vivo in thigh muscle tissue. The analytes of interest were quantified using a Prominence HPLC system coupled with a tandem mass spectrometer. Results: This work showed that through the carnitine-specific transporter OCTN2, imatinib and carnitine intake competed unequally and intracellular carnitine concentrations were significantly reduced. In contrast, carnitine preincubation did not influence imatinib cell intake or interfere with leukemia cell targeting. Blocking the intracellular supply of carnitine with imatinib significantly reduced the production of most Krebs cycle metabolites and ATP. However, subsequent carnitine supplementation rescued mitochondrial energy production. Due to specific inhibition of OCTN2 activity, the influx of carnitine was blocked and mitochondrial energy metabolism was impaired in muscle cells in vitro and in thigh muscle tissue in a mouse model. Conclusions: This preclinical experimental study revealed detrimental effect of imatinib on carnitine-mediated energy metabolism of muscle cells providing a possible molecular background of the frequently occurred side effects during imatinib therapy such as fatigue, muscle pain and cramps.
Bleeding with gastrointestinal and ureteral ulcers after gefitinib treatment: a case report

Jian Xiao,Wenjing Ruan,Ning Li,Dongdong Huang

DOI: https://doi.org/10.21037/tcr-20-3420

2021-04-01

Translational Cancer Research

Abstract:Epidermal growth factor receptor (EGFR) inhibitors, as a first-line drug treatment in the EGFR-sensitive mutation of advanced non-small-cell lung cancer (NSCLC), has been used in a wide variety of malignancies. These therapies have various troublesome side effects including diarrhea, stomatitis, mucositis, rash, dry skin and paronychia which may impact a patient's clinical outcome in addition to their beneficial effects. Here, we report a rare case of a 69-year-old male having advanced NCSLC treated with gefitinib, who developed EGFR tyrosine kinase inhibitor (TKI)-related multiple ulcers accompanied by bleeding. After a detailed examination and multidisciplinary discussion, we have learnt that early identification of gastrointestinal (GI) bleeding and blood in urine is due to targeted drugs rather than other causes such as ulcer and stones. Good results have also been achieved by reducing drug dosage under close observation. So far, the patient has been followed up for 15 months, and his condition remained stable. Up to now, there is no case of such severe side effect having been found, and no guidelines recommended for handling such adverse events. Through clinical case sharing, early recognition and proactive management are particularly important in order to minimize appropriately the effect of these adverse events. The whole course of a disease can be vividly illustrated through a case report, so as to provide more effective guiding principles for clinicians.

oncology
Imatinib-induced dermatomyositis sine dermatitis - a rare case report

Augusto Silva,Vasco C. Romão,Raquel Campanilho-Marques

DOI: https://doi.org/10.3389/fimmu.2024.1398453

IF: 7.3

2024-04-29

Frontiers in Immunology

Abstract:Idiopathic Inflammatory Myopathies are rare conditions with several heterogeneous disease subtypes. They can range from limited muscle or skin involvement to severe, systemic, life-threatening disease. Although the etiology is unknown, some evidence suggests a role for external agents, particularly drugs. Herein, we present a case of a 71-year-old woman with chronic myeloid leukemia who developed imatinib-induced dermatomyositis sine dermatitis . The presentation was predominantly muscular, characterized by proximal muscle weakness and myalgia of the lower limbs, with positive anti-Mi2a antibodies. Spontaneous recovery was observed after drug discontinuation, without the need for immunosuppressive therapy. This is the first confirmed description of an imatinib-induced dermatomyositis sine dermatitis. It reflects the importance of a high awareness from rheumatologists and hematologists to accurately anticipate and identify similar situations.

immunology
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure

Sara Gagno,Angela Buonadonna,Chiara Dalle Fratte,Michela Guardascione,Martina Zanchetta,Bianca Posocco,Marco Orleni,Giovanni Canil,Rossana Roncato,Erika Cecchin,Giuseppe Toffoli

DOI: https://doi.org/10.1007/s40199-023-00465-z

Abstract:Background: Chronic oral anticancer therapies, are increasingly prescribed and present new challenges including the enhanced risk of overlooked drug-drug interactions (DDIs). Lengthy treatments and patients' management by different professionals can lead to serious prescribing errors that therapeutic drug monitoring (TDM) can help identifying thus allowing a more effective and safer treatment of patients with polypharmacy. Objectives: This report aims to exemplify how an intensified pharmacological approach could help in the clinical monitoring of patients on chronic treatments. Methods: A patient with gastrointestinal stromal tumor was referred to our clinical pharmacology service due to tumor progression while on imatinib therapy. The investigation was based on TDM, pharmacogenetics, DDI evaluation and Circulating tumor DNA (ctDNA) analysis. The patient underwent repeated blood samplings to measure imatinib and norimatinib plasma concentrations through a validated LC-MS/MS method. Polymorphisms affecting genes involved in imatinib metabolism and transport were investigated using SNPline PCR Genotyping System. Drug-drug interactions were evaluated though Lexicomp. ctDNA analysis was performed on MiSeq platform. Results: TDM analysis revealed that the patient was underexposed to imatinib (Cmin = 406 ng/mL; target Cmin = 1100 ng/mL). Subsequent DDI analysis highlighted a dangerous interaction with carbamazepine, via CYP3A4 and P-gp strong induction, omitted at the time of imatinib treatment start. No relevant pharmacogenetic variants were identified and appropriate compliance to treatment was ascertained. ctDNA monitoring was performed to assess potential tumor-related resistance to imatinib. Carbamazepine was cautiously switched to a non-interacting antiepileptic drug, restoting IMA plasma concentration (i.e. Cmin = 4298 ng/mL). The progression of the disease, which in turn led to the patient's death, was also witnessed by an increasing fraction of ctDNA in plasma. Conclusion: The active pharmacological monitoring allowed the identification of a dangerous previously over-looked DDI leading to IMA under-exposure. The switch to a different antiepileptic treatment, reversed the effect of DDI, restoring therapeutic IMA plasmatic concentrations.
Acute ischemic intestinal necrosis as a rare side effect of nilotinib

L Li,W Liu,Z Zeng,S Chen

DOI: https://doi.org/10.4103/njcp.njcp_33_18

2019-01-01

Nigerian Journal of Clinical Practice

Abstract:Tyrosine kinase inhibitors (TKIs) are highly effective therapies for chronic myeloid leukemia (CML). However, continuous administration of TKIs could lead to toxicity that could induce serious vascular disorders. Nilotinib, a second-generation TKI, has been approved for patients with CML in the chronic phase or accelerated phase, after resistance to imatinib has been identified, or as a first-line treatment. In comparison to other TKIs, nilotinib has been associated with a higher incidence of cardiovascular events, such as peripheral artery occlusive disease. We present a CML patient who developed acute ischemic bowel necrosis and perforation during nilotinib therapy.

medicine, general & internal
Development of Sunitinib in the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

WANG Ke,DING Ke-feng

DOI: https://doi.org/10.3760/cma.j.issn.1673-4203.2011.02.018

2011-01-01

Abstract:Sunitinib malate (SU11248 ,Sutent) is an orally available small-molecule multitargeted tyrosine kinase inhibitor that has potent anti-angiogenic and antitumour activities.In 2006 sunitinib was approved by FDA for imatinib intolerant gastrointestinal stromal tumors (GIST) patients or imatinib resistant GIST patients.This article review the molecular-based mechanism,the mechanism of resistance,the biomarker,the clinical trials and the adverse effects of sunitinib in the treatment of imatinib-resistant GIST.
A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

J. Guo,L. Si,Y. Kong,X. W. Xu,K. T. Flaherty,C. L. Corless,Y. Y. Zhu,L. Li,H. F. Li

DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.8527

IF: 45.3

2010-01-01

Journal of Clinical Oncology

Abstract:8527 Background: KIT is an important oncogene in acral and mucosal melanomas, which account for 70% of melanomas in Asian patients (Pts). We conducted a phase II study (NCT00881049) to test the KIT inhibitor imatinib in metastatic melanoma pts with KIT aberrations. Methods: Pts with metastatic or unresectable melanoma whose tumor had KIT aberrations (KIT mutation [mut] and/or KIT gene DNA amplification [amp]) and who had measurable disease were enrolled. Pts received imatinib 400 mg/d continually until disease progression or intolerable toxicity. The dosage of Imatinib was escalated to 600 mg or 800 mg per day if progression was observed. Response was assessed monthly using RECIST criteria. The endpoints were progression-free survival (PFS), overall response rate (ORR) and toxicity. Results: Of 390 cases screened, 67 (17.4%) had a KIT mut or amp: 26/137 (18.9%) acral, 21/110 (19.1%) mucosal, 9/26 (34.6%) CSD, 6/75 (8%) NCSD, 5/42 (11.9%) unknown primary. 41 (10.5%) had a mut only; 23 (5.9%) had an amp only; 3 (0.8%) had both. Thus far, 28 patients have been treated with 26 pts currently evaluable: 5 stage M1a/3 M1b/20 M1c; median prior therapies: 2. Six patients (21%) achieved PR (5 mut, 1 amp, 4∼10+m); nine patients (35%) received SD (≥ 3 m, 3.5∼9+m). Pts who failed on 400mg also failed on escalation to 600mg and could not tolerate 800mg due to toxicities. Samples of new or progressive lesions were obtained from 5 PR pts after they failed on imatinib 400mg, and were analyzed in KIT, BRAF and PDGFRA. In one pt (emerging metastasis in liver) new mutations were found in BRAF (V600E) and PDGFRA (W559stop) which were wild-type before treatment, and loss of the KIT mutation present at baseline. Common toxicities at 400 mg were rash, vomiting, edema and myelosuppresion. Conclusions: Imatinib (400mg/d) provides a beneficial therapeutic effect for a significant proportion of Chinese metastatic melanoma pts with KIT aberrations. Acquired genetic mutations after treatment may account for emergence of resistance in some pts. Supported by the National Natural Science Foundation of China (30973483), 985-2-085-113 and Novartis Oncology in China. No significant financial relationships to disclose.
Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

Zeng Wang,Liyu Jiang,Hao Yan,Zhifei Xu,Peihua Luo

DOI: https://doi.org/10.1080/17512433.2021.1894129

2021-01-01

Expert Review of Clinical Pharmacology

Abstract:Introduction: Nilotinib is a second-generation tyrosine kinase inhibitor (TKI) targeting BCR/ABL, which is used for the first-line treatment of newly diagnosed chronic myeloid leukemia (CML) patients and the second-line treatment of most CML patients who are resistant or intolerant to prior therapy that includes imatinib. In addition to common adverse reactions, long-term use of nilotinib shows some toxicities that are different from those of occurring during other BCR/ABL TKI treatments, such as cardiovascular toxicity. It is life-threatening, which would affect not only the choice of initial treatment of CML patients but also the safety of long-term medication. Areas covered: Through searching literature and reports from PubMed and clinical trials, here we review a profile of the adverse effects induced by nilotinib. We also discuss the potential molecular toxicological mechanisms and clinical management, which may provide strategies to prevent or intervene the toxicity associated with nilotinib. Expert opinion: Severe adverse effects associated with nilotinib limit its long-term clinical application. However, the exact mechanisms underlying these toxicities remain unclear. Future research should focus on the developing strategies to reduce the toxicities of nilotinib as well as to avoid similar toxicity in the development of new drugs.
Imatinib Mesylate Alone for Refractory Advanced Gastrointestinal Stromal Tumor

Lin Shen,Mao-lin Jin

DOI: https://doi.org/10.3760/j.issn:0253-3766.2004.11.015

2004-01-01

Abstract:OBJECTIVETo evaluate the efficacy and safety of imatinib mesylate in the treatment of patients as preoperative supplement, or used alone for unresectable and(or) metastatic gastrointestinal stromal tumor (GIST).METHODSA total of 30 cases with advanced GIST were proved pathologically. Among them, CD117 was detected positive in 29 patients; 2 patients received imatinib mesylate before operation and 28 patients with unresectable and(or) metastatic GIST received oral imatinib mesylate daily at dose of 200-600 mg. Three patients were lost in follow-up and the objective effect was evaluated in 25 patients.RESULTSFifteen of 25 patients (60.0%) achieved partial response (PR); 5 (20.0%) had stable disease (SD) and 5 (20.0%) had progression disease (PD). Median time to progression (mTTP) was more than 13 months during which most experienced benefit. Twenty-two patients had been followed-up more then 1 year. The 1-year survival rate was 86.4%. The overall median survival has not been obtained to date. Twenty-seven patients were valuable for the toxicity assessment according to the WHO standard. The main toxicity included grade I-II edema of periorbital area and lower limb in 85.2% (23/27) patients, leukopenia was present in 40.7% (11/27) and intratumoral bleeding in 7.4% (2/27). Other toxicities included mild fatigue (29.6%), abdominal pain (14.8%), efflorescence (11.1%), nausea and vomiting (18.5%).CONCLUSIONAs an inhibitor of tyrosine kinase, imatinib mesylate is generally well tolerated and has been proved to be effective and safe during prolonged treatment of patients with advanced gastrointestinal stromal tumors.
Digestive Tract Hemorrhage Due to Complications with Gastrointestinal Stromal Tumor Treated with Sunitinib: A Case Report.

Yan Liu,He-Long Zhang,Ye Zhang,Jia-Zhuan Mei,Hong-Wei Lin,Yan-Wei Guo,Rui-Jun Li,Xiang-Rui Meng,Gui-Ju Liu,Min Li,Peng Xiao,Hua Bai

DOI: https://doi.org/10.3892/ol.2012.1050

2012-01-01

Oncology Letters

Abstract:Gastrointestinal stromal tumors (GISTs) are rare, and account for 1% of all gastrointestinal neoplasms. GISTs are the most frequent mesenchymal tumors of the gastrointestinal tract. However, the clinical and pathological characteristics of these neoplasms are not adequately understood. The best treatment approach for GISTs remains unclear. In the present study, we report a case of a GIST originating from the stomach. A digestive tract hemorrhage occurred as a complication of sunitinib treatment. This is the first report of a digestive tract hemorrhage due to sunitinib treatment.
Sand transport and burrow construction in sparassid and lycosid spiders

R. Foelix,I. Rechenberg,Bruno Erb,A. Albín,A. Aisenberg

DOI: https://doi.org/10.1636/JoA-S-16-058.1

2017-12-07

Abstract:Abstract A desert-living spider sparassid (Cebrennus rechenbergi Jäger, 2014) and several lycosid spiders (Evippomma rechenbergi Bayer, Foelix & Alderweireldt 2017, Allocosa senex (Mello-Leitão, 1945), Geolycosa missouriensis (Banks, 1895)) were studied with respect to their burrow construction. These spiders face the problem of how to transport dry sand and how to achieve a stable vertical tube. Cebrunnus rechenbergi and A. senex have long bristles on their palps and chelicerae which form a carrying basket (psammophore). Small balls of sand grains are formed at the bottom of a tube and carried to the burrow entrance, where they are dispersed. Psammophores are known in desert ants, but this is the first report in desert spiders. Evippomma rechenbergi has no psammophore but carries sand by using a few sticky threads from the spinnerets; it glues the loose sand grains together, grasps the silk/sand bundle and carries it to the outside. Although C. rechenbergi and E. rechenbergi live in the same environment, they employ different methods to carry sand. Geolycosa missouriensis lives in a moister habitat and produces solid sand pellets in which sand grains are caked together (without silk threads); the compact pellets are flung away from the burrow entrance by a rapid extension of the first legs. The spiders stabilize the developing tube inside by repeatedly adding silk rings, while digging down. This wall is very thin, consisting of only a few layers of crisscrossing silk threads. An excavated burrow collapses immediately, indicating that the stability is not due to the silk. Instead, the tight interconnection of neighboring sand grains—as in a vault—yields the necessary solidity to the burrow.
Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management

I Manousaridis,S Mavridou,S Goerdt,M Leverkus,J Utikal

DOI: https://doi.org/10.1111/j.1468-3083.2012.04546.x

Abstract:Mutations in genes encoding for proteins along the RAS-RAF-MEK-ERK pathway have been detected in a variety of tumor entities, including malignant melanoma, thyroid, colonic and ovarian carcinomas, and some sarcomas. Thus, a number of inhibitors of this pathway have been developed, whose antitumor potential is currently being assessed in different clinical trials. Up to now one drug of this category (vemurafenib) has been approved by the FDA and the European Commission for late-stage melanoma. Although these new targeted anticancer therapies are generally considered to be safe and well tolerated, certain toxicities have been attributed to them, with cutaneous side effects being perhaps the most frequent amongst them. Based on results of clinical trials and on case series, a distinct profile of cutaneous toxicity has been observed, which is similar to that of EGFR and multikinase inhibitors. As exanthema, palmar-plantar erythrodysesthesia syndrome, hyperkeratosis, xerosis, pruritus, photosensitivity, and paronychia, can be controlled in most cases with common conservative modalities, special attention should be given to the early detection of epithelial skin tumors (mainly keratoakanthomas) that can be induced during therapy with these agents. This report reviews all current published data on cutaneous side effects of RAS-RAF-MEK-ERK pathway inhibitors, and attempts to provide the clinician with clear hints for their management.
Tyrosine Kinase Inhibitor Imatinib Mesylate Induces Generalized Skin Hypopigmentation in Chinese Patients with Chronic Myelogenous Leukemia.

Yingjia Wang,Yanmin Zhao,Lizhen Liu,Weijie Cao,Kangni Wu,Longyan Chen,Xiaohong Yu,He Huang

DOI: https://doi.org/10.1182/blood.v116.21.4475.4475

IF: 20.3

2010-01-01

Blood

Abstract:Abstract 4475 Imatinib mesylate is a selective tyrosine kinase inhibitor targeting BCR-ABL fusion protein. In the therapy of either interferon refractory or newly diagnosed chronic myeloid leukemia (CML), imatinib significantly improved the prognosis of the disease, albeit with typically mild to moderate adverse effects. In recent years, increasing attention has been focused on the skin hypopigmentation developed after the initiation of imatinib therapy, especially in Asian countries such as India, with the incidence between 33% and 85%, though sparsely reported in western countries. The inhibition of c-kit by imatinib may be a possible explanation, but the exact mechanism for this hypopigmentation caused by imatinib and its potential risk in patients is poorly understood. Here we report our clinical observation of this side effect of imatinib therapy among Chinese CML patients in our institution, as well as a brief in vitro study aiming to investigate the mechanism of the hypopigmentory effect and evaluate its potential risk. Among 116 patients who took imatinib for CML therapy, 90 of them (77.6%) had reported to develop generalized hypopigmentation or whitening in the skin. This side effect usually developed within 3 months after initiation of imatinib, persistent during the therapy, and reversible upon imatinib discontinuation, according to our interviews and observation. More interestingly, in three of these CML patients who originally had vitiligo, the cosmetic appearance seemed to be improved during imatinib therapy due to the whitening effect on normal pigmented skin areas. To further confirm and understand this side effect, we examined the impact of imatinib on cultured normal human melanocytes derived from the foreskins of healthy Chinese adults. Melanocytes were treat with various concentrations of imatinib (1~16 μ M) for different periods of time (1~7 days). Cell proliferation and apoptosis were detected by cell counting kit-8 and flow cytometric assay, respectively. The melanogenic activity of the melanocytes was detected by melanin content assay and tyrosinase activity assay. Moreover, the role of stem cell factor (SCF) and its receptor c-kit in imatinib induced hypopigmentation were investigated. We found that imatinib not only concentration-dependently inhibited melanocyte proliferation in vitro (IC50=6.23 μ M), but also resulted in massive melanocyte apoptosis at concentrations higher than 8 μ M (P Disclosures: No relevant conflicts of interest to declare.
Imatinib Impairs CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168 in Vitro

Jinfei Chen,Anita Schmitt,Baoan Chen,Markus Rojewski,Mark Ringhoffer,Stephanie von Harsdorf,Jochen Greiner,Philippe Guillaume,Hartmut Döhner,Donald Bunjes,Michael Schmitt

DOI: https://doi.org/10.1007/s00262-006-0232-9

2006-01-01

Abstract:The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate is highly effective in the front-line treatment of chronic myeloid leukemia (CML) and is increasingly used in patients with residual disease or relapse after allogeneic stem cell transplantation (allo-SCT). Since an impairment of anti-viral CD8+ T-lymphocyte function by imatinib has been described, we question whether imatinib also affects specific anti-leukemic CD8+ T lymphocytes generated from the peripheral blood of healthy donors, and of CML patients after allo-SCT. Here, we assessed CD8+ T-cell expansion and function from healthy donors and patients with CML. The release of IFN-gamma and granzyme B by CD8+ T-lymphocytes specific for R3, a recently described T-cell epitope peptide derived from a leukemia-associated antigen designated RHAMM/CD168 (receptor for hyaluronic acid mediated motility), was inhibited by imatinib in a dose-dependent fashion (range: 1-25 microM). These T cells were able to lyse cognate peptide labeled T2 cells and CD34+ CML progenitor cells. This lysis was inhibited by imatinib. The inhibitory effect was not associated with an increased rate of apoptosis of T cells and reversible after removal of imatinib. In the light of these findings, clinical administration of imatinib might result in the reduction of efficacy of the graft-versus-leukemia effect or other T-cell-based immunotherapies.
Correction: OVATE Family Protein 8 Positively Mediates Brassinosteroid Signaling through Interacting with the GSK3-like Kinase in Rice

Chao Yang,Wenjin Shen,Yong He,Z. Tian,Jianxiong Li

DOI: https://doi.org/10.1371/journal.pgen.1006970

IF: 4.5

2017-08-01

PLoS Genetics

Abstract:[This corrects the article DOI: 10.1371/journal.pgen.1006118.].
The blue palate-A case series of imatinib-related oral pigmentation and literature review

Christopher C Donnell,Richard L Walton,Marco Carrozzo

DOI: https://doi.org/10.1016/j.oooo.2020.10.015

Abstract:Pigmented oral mucosal lesions are diverse, and differential diagnosis can range from benign conditions such as oral melanotic macule to malignancies such as oral malignant melanoma. Imatinib mesylate is a tyrosine kinase inhibitor used as a first-line medication in the management of oncohematological conditions such as chronic myeloid leukemia and gastrointestinal stromal tumors. Side effects of imatinib therapy are common, and paradoxically imatinib has been associated with both hypo- and hyperpigmented lesions, the underlying mechanism for which is still unclear. Hyperpigmentation associated with imatinib therapy is a potentially underreported phenomenon. This article presents an in-depth, clinicopathological review of the literature surrounding imatinib-related hyperpigmentation, alongside a case series of imatinib-related oral pigmentation with notable practical learning points. A pragmatic flowchart to help clinicians in the diagnosis and management of oral pigmented lesions is provided, as well as advice on the application of the ABCDE criteria to standardize recording of oral pigmented lesions.

Extension block with Kirschner wire for fracture dislocation of the distal interphalangeal joint.

Effect of imatinib on oral wound healing after extraction: A rare case report

Imatinib mesylate-induced lichenoid drug eruption

Imatinib mesylate-induced acute hepatotoxicity

Hypotensive Effects of Interval vs. Continuous Aerobic Exercise in Metabolic Syndrome Patients.: 1950 Board #102 June 2, 2: 00 PM - 3: 30 PM.

Imatinib Therapy of Chronic Myeloid Leukemia Significantly Reduces Carnitine Cell Intake, Resulting in Adverse Events

Bleeding with gastrointestinal and ureteral ulcers after gefitinib treatment: a case report

Imatinib-induced dermatomyositis sine dermatitis - a rare case report

The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure

Acute ischemic intestinal necrosis as a rare side effect of nilotinib

Development of Sunitinib in the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

Imatinib Mesylate Alone for Refractory Advanced Gastrointestinal Stromal Tumor

Digestive Tract Hemorrhage Due to Complications with Gastrointestinal Stromal Tumor Treated with Sunitinib: A Case Report.

Sand transport and burrow construction in sparassid and lycosid spiders

Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management

Tyrosine Kinase Inhibitor Imatinib Mesylate Induces Generalized Skin Hypopigmentation in Chinese Patients with Chronic Myelogenous Leukemia.

Imatinib Impairs CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168 in Vitro

Correction: OVATE Family Protein 8 Positively Mediates Brassinosteroid Signaling through Interacting with the GSK3-like Kinase in Rice

The blue palate-A case series of imatinib-related oral pigmentation and literature review